[Additional measures of treatment in patients with renal anemia]

Treatment of renal anemia with erythropoiesis-stimulating agents (ESA) is performed with the addition of iron, and other drugs and adjuvants to epoetin therapy to reach target hemoglobin. In achieving the ultimate goal should be to provide adequate dialysis, monitor the nutritional status of patients, improve patient response to treatment with adjuvants to epoetin therapy (vitamins, androgens, antioxidants) and in exceptional circumstances a transfusion of red blood cells. The article discussed several elements of the additional measures for the treatment of patients with renal anemia.

Additional measures of treatment in patients with renal anemia affect the improvement of anemia in patients with chronic kidney failure, but not in respectable extent. They can reduce the required dose of erythropoiesis-stimulating agents (ESA) and improve the effectiveness of iron. Some measures are strictly defined indications and application of targeted patients (e.g., reduced response to the ESA). For most measures is not recommended as a routine application. Some measures must be implemented to strengthen the supervision of serious side effects.